Background The pathogenesis and etiology of endometrial polyps has not been elucidated. In this study, we aimed to examine the pathogenic mechanisms of endometrial polyp development using immunohistochemistry. We evaluated the expression of galectin-3 and cyclooxgenase-2 (COX-2) during the menstrual cycle in premenopausal women with endometrial polyps or normal endometrium.
Methods Thirty-one patients with endometrial polyps and 50 healthy control patients were included in this study. The levels of expression of COX-2 and galectin-3 were studied by immunohistochemistry.
Results The percentage of COX-2–positive cells and the intensity of COX-2 staining in the endometrium did not vary during the menstrual cycle either in the control group or in patients with endometrial polyps. However, expression of galectin-3 was significantly lower in endometrial polyps and during the proliferative phase of the endometrium compared with the secretory phase.
Conclusions Our data suggests that the pathogenesis of endometrial polyps does not involve expression of COX-2 or galectin-3.
Citations
Citations to this article as recorded by
Research Progress in the Treatment of Endometrial Polyps 秀芬 蔡 Advances in Clinical Medicine.2024; 14(01): 1772. CrossRef
ER and COX2 expression in endometrial hyperplasia processes Nataliia Tsyndrenko, Mykola Lyndіn, Kateryna Sikora, Andrew Awuah Wireko, Toufik Abdul-Rahman, Nataliia Hyriavenko, Anatolii Romaniuk Medicine.2023; 102(33): e34864. CrossRef
Novel microarchitecture of human endometrial glands: implications in endometrial regeneration and pathologies Nicola Tempest, Christopher J Hill, Alison Maclean, Kathleen Marston, Simon G Powell, Hannan Al-Lamee, Dharani K Hapangama Human Reproduction Update.2022; 28(2): 153. CrossRef
Variances in the Level of COX-2 and iNOS in Different Grades of Endometrial Cancer Marcin Oplawski, Konrad Dziobek, Nikola Zmarzły, Beniamin O. Grabarek, Robert Kiełbasiński, Przemysław Kieszkowski, Piotr Januszyk, Karol Talkowski, Michał Schweizer, Piotr Kras, Andrzej Plewka, Dariusz Boroń Current Pharmaceutical Biotechnology.2020; 21(1): 52. CrossRef